{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:03:54Z","timestamp":1778947434500,"version":"3.51.4"},"reference-count":48,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to investigate the prescription of beta\u2010blockers (\u03b2\u2010blockers) for patients with asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cross\u2010sectional study using the National Patient Sample (NPS) of the Health Insurance Review and Assessment Service (HIRA) of South Korea, \u03b2\u2010blockers and asthma medications were investigated using generic name codes provided by HIRA. Concomitant administration was identified when a \u03b2\u2010blocker and an asthma medication were co\u2010prescribed in one billing statement or when separate \u03b2\u2010blocker and asthma prescriptions had overlapping dates of use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 1027 patients with asthma who were prescribed non\u2010selective \u03b2\u2010blockers (non\u2010SBs), 3087 non\u2010SB prescriptions were identified, of which 62.3% and 37.3% were for carvedilol and propranolol, respectively. Of the 906 patients with asthma prescribed selective \u03b2\u2010blockers (SBs), 2942 SB prescriptions were identified, of which 48.5%, 28.3%, and 20.3% were for bisoprolol, atenolol, and nebivolol, respectively. Overall, 2149 non\u2010SB and 2124 SB prescriptions with overlapping use dates with asthma medications were identified, which were prescribed to 726 and 657 patients, accounting for 70.7% and 72.5% of the patients receiving non\u2010SBs and SBs, respectively. \u03b22\u2010agonists accounted for 39.9% of the concomitant asthma medications with overlapping dates of use with non\u2010SBs. Co\u2010prescribing of bronchodilators occurred at a rate of 38.7% and 45.1% for the 3087 non\u2010SB prescriptions and 2942 SB prescriptions, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Carvedilol and propranolol accounted for half of all \u03b2\u2010blockers prescribed to asthma patients. Prescribing \u03b2\u2010blockers to patients with asthma requires caution to prevent exacerbation of asthma and drug interactions between \u03b2\u2010blockers and co\u2010prescribed asthma medications.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5806","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T03:50:19Z","timestamp":1722570619000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world prescription of beta\u2010blockers in patients with asthma"],"prefix":"10.1002","volume":"33","author":[{"given":"Jihyun","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research Inje University  Gimhae Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-9880","authenticated-orcid":false,"given":"Pusoon","family":"Chun","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research Inje University  Gimhae Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02730-2021"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"e_1_2_13_4_1","unstructured":"KOIS.Medical expenses by disease category. Accessed March 5 2023https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=177&tblId=DT_11702_N112&conn_path=I2"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201703-259OC"},{"issue":"2","key":"e_1_2_13_6_1","first-page":"121","article-title":"International Union of Pharmacology nomenclature of adrenoceptors","volume":"46","author":"Bylund DB","year":"1994","journal-title":"Pharmacol Rev"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573402114666180918102735"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2012.05.007"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2019.02.023"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557515666151016125948"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19020"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199202030-00005"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104587"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1235"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79837-3"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0781-0"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13006"},{"key":"e_1_2_13_18_1","unstructured":"KOICD.Disease Statistics. Accessed March 5 2023https:\/\/www.koicd.kr\/stt\/statDisease.do#"},{"key":"e_1_2_13_19_1","unstructured":"Korean Society of Hypertension (KSH)\u2010Hypertension Epidemiology Research Working Group. Korea Hypertension Fact Sheet.Clinical Hypertension (inpress). Accessed May 24 20232021https:\/\/www.koreanhypertension.org\/reference\/guide?mode=read&idno=4581"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"issue":"6","key":"e_1_2_13_21_1","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","journal-title":"Hypertension."},{"key":"e_1_2_13_22_1","unstructured":"Global Initiative for Asthma.Global strategy for asthma management and prevention.2022. Accessed January 26 2023www.ginasthma.org"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008"},{"key":"e_1_2_13_24_1","unstructured":"Healthcare Bigdata Hub.Patient sample data guide. Accessed March 5 2023https:\/\/opendata.hira.or.kr\/op\/opc\/selectPatDataAplInfoView.do"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.08.005"},{"key":"e_1_2_13_26_1","unstructured":"DATA.GO.KR.HIRA_Drug Price Master_Medicine Main Ingredient. Accessed January 26 2023https:\/\/www.health.kr\/drug_info\/basedrug\/main_ingredient.html"},{"key":"e_1_2_13_27_1","volume-title":"Drug Class Review on Beta Adrenergic Blockers: Final Report","author":"Helfand M","year":"2007"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2016.24.4.157"},{"key":"e_1_2_13_29_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.Definition and general considerations. Accessed January 26 2023https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/#General"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2016.79.3.111"},{"key":"e_1_2_13_31_1","unstructured":"NHS information.Bronchodilators.2022. Accessed December 4 2023https:\/\/www.nhs.uk\/conditions\/bronchodilators\/"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216526"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045343"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.5.684"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12181"},{"key":"e_1_2_13_36_1","unstructured":"Global strategy for asthma management and prevention.2019. Accessed February 22 2024.https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf."},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.38.2.108"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)00459-X"},{"key":"e_1_2_13_39_1","unstructured":"GlaxoSmithKline.COREG\u00ae. Accessed June 26 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020297s013lbl.pdf"},{"key":"e_1_2_13_40_1","unstructured":"Akrimax Pharmaceuticals LLC.Inderal\u00ae. Accessed June 26 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016418s080 016762s017 017683s008lbl.pdf"},{"key":"e_1_2_13_41_1","unstructured":"Bayer HealthCare Pharmaceuticals Inc.BETAPACE\u00ae. Accessed June 26 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019865s019lbl.pdf"},{"key":"e_1_2_13_42_1","unstructured":"ISTA.Pharmaceuticals\u00ae Inc. ISTALOL\u00ae. Accessed June 26 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021516s005lbl.pdf"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-9-200211050-00035"},{"key":"e_1_2_13_44_1","unstructured":"The Korean Academy of tuberculosis and respiratory diseases (KATRD).Guidelines for the diagnosis and treatment of asthma. Accessed February 18 20242022https:\/\/www.lungkorea.org\/bbs\/index.html?code=guide"},{"key":"e_1_2_13_45_1","unstructured":"HIRA.Drug Utilization Review (DUR). Accessed May 5 2022https:\/\/www.hira.or.kr\/eng\/about\/05\/01\/04\/index.html"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.11.019"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100281"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1843.2000.00236.x"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05064.x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T01:53:09Z","timestamp":1732153989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/pds.5806"],"URL":"https:\/\/doi.org\/10.1002\/pds.5806","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5806"}}